SCHEMBL7218658

SCHEMBL7218658

COC(=O)c1c(C)[nH]c2c(OC)cccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.59
GAA P10253 4/20 0.58
GLA P06280 1/20 0.58
ALDH1A1 P00352 8/20 0.56
KMT2A Q03164 5/20 0.56
KDM4E B2RXH2 5/20 0.56
HPGD P15428 4/20 0.56
MEN1 O00255 4/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
POLB P06746 3/20 0.56
MAPT P10636 3/20 0.56
MCL1 Q07820 2/20 0.56
TSHR P16473 1/20 0.56
HTT P42858 1/20 0.56
RECQL P46063 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
THRB P10828 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
NQO2 P16083 1/20 0.50
ALOX12 P18054 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7839279 0.82 NR4A2 (0.59) NR4A2GAAALDH1A1KMT2AKDM4E
SCHEMBL5237030 0.82 NR4A2 (0.59) NR4A2GAAALDH1A1KMT2AKDM4E
SCHEMBL7217500 0.81 ALDH1A1 (0.52) NR4A2GAAGLAALDH1A1KMT2A
SCHEMBL28025010 0.80 GAA (0.53) NR4A2GAAGLAALDH1A1KMT2A
SCHEMBL7410285 0.80 GAA (0.50) GAAGLAALDH1A1KMT2AKDM4E
SCHEMBL7222685 0.77 NR4A2 (0.46) NR4A2GAAGLAALDH1A1KMT2A
SCHEMBL7839166 0.75 NR4A2 (0.51) NR4A2GAAALDH1A1KMT2AKDM4E
SCHEMBL7782575 0.75 CNR2 (0.49) GAAGLAALDH1A1KMT2AKDM4E
SCHEMBL8070069 0.75 ALDH1A1 (0.46) GAAGLAALDH1A1KMT2AKDM4E
SCHEMBL3263699 0.75 GAA (0.48) NR4A2GAAGLAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993523-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2015-03-31 US disclosed
US-20130309247-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2013-11-21 US disclosed
EP-2651919-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-10-23 EP disclosed
WO-2012080271-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2012-06-21 WO disclosed
US-6653304-B2 Antiarthritic agents; skin disorders; anticarcinogenic agents BRISTOL-MYERS SQUIBB CO. 2003-11-25 US disclosed
EP-1254115-A2 CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS FOR TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES Bristol-Myers Squibb Company (US) 2002-11-06 EP disclosed
US-20020119972-A1 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases BRISTOL-MYERS SQUIBB COMPANY 2002-08-29 US disclosed
WO-2001058869-A2 CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS IN TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130309247-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 NR4A2 3995/4885GAA 1947/4885GLA 1960/4885
US-20020119972-A1 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases CNR1, CNR2, GPR18 NR4A2 146/4885GAA 4268/4885GLA 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.